Among 168 patients who underwent molecular testing, 34 (20.2%) had double/triple hit lymphoma. Most had Ann Arbor stage III to stage IV disease (78.9%) and an ECOG performance of 1 or lower (91%).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback